Anamorelin HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 200230

CAS#: 861998-00-7 (HCl salt)

Description: Anamorelin, also known as RC-1291 or ONO-7643, is the orally bioavailable, small-molecule ghrelin mimetic with appetite-stimulating and anabolic activities. Anamorelin binds to and stimulates the growth hormone secretagogue receptor (GHSR) centrally, thereby mimicking the appetite-stimulating and growth hormone-releasing effects of grhelin. Stimulation of GHSR may also reduce the production of the pro-inflammatory cytokines TNF-alpha and interleukin-6, which may play a direct role in cancer-related loss of appetite.


Price and Availability

Size
Price

10mg
USD 90
100mg
USD 250
1g
USD 1350
10g
USD 5850
Size
Price

25mg
USD 120
200mg
USD 450
2g
USD 2350
20g
USD 9950
Size
Price

50mg
USD 150
500mg
USD 750
5g
USD 3650
50g
Ask price

Anamorelin hydrochloride, (racemic, purity >98%), purity > 98%, is in stock. The same day shipping out after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 200230
Name: Anamorelin HCl
CAS#: 861998-00-7 (HCl salt)
Chemical Formula: C31H43ClN6O3
Exact Mass:
Molecular Weight: 583.16
Elemental Analysis: C, 63.85; H, 7.43; Cl, 6.08; N, 14.41; O, 8.23


Synonym: RC 1291; RC1291; RC-1291; RC 1291HCl; ONO7643; ONO-7643; ONO 7643; Anamorelin HCl

IUPAC/Chemical Name: 2-amino-N-((R)-1-((R)-3-benzyl-3-(1,2,2-trimethylhydrazinecarbonyl)piperidin-1-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-2-methylpropanamide hydrochloride

InChi Key: VFYAEUWJFGTGGO-GHTUPXNNSA-N

InChi Code: InChI=1S/C31H42N6O3.ClH/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22;/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39);1H/t26-,31-;/m1./s1

SMILES Code: CC(C)(N)C(N[C@H](CC1=CNC2=C1C=CC=C2)C(N3C[C@](C(N(C)N(C)C)=O)(CC4=CC=CC=C4)CCC3)=O)=O.[H]Cl.


Technical Data

Appearance:
white to off-white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in water or buffer.

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Related:
861998-00-7 (Anamorelin HCl salt)
249921-19-5 (Anamorelin free base)


References

1: Zhang H, Garcia JM. Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opin Pharmacother. 2015 Jun;16(8):1245-53. doi: 10.1517/14656566.2015.1041500. Epub 2015 May 6. PubMed PMID: 25945893.

2: von Haehling S, Anker SD. Treatment of cachexia: An overview of recent developments. Int J Cardiol. 2015 Apr 1;184:736-42. doi: 10.1016/j.ijcard.2014.10.026. Epub 2014 Oct 16. PubMed PMID: 25804188.

3: Baracos VE. Skeletal muscle anabolism in patients with advanced cancer. Lancet Oncol. 2015 Jan;16(1):13-4. doi: 10.1016/S1470-2045(14)71185-4. Epub 2014 Dec 16. PubMed PMID: 25524803.

4: Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015 Jan;16(1):108-16. doi: 10.1016/S1470-2045(14)71154-4. Epub 2014 Dec 16. PubMed PMID: 25524795.

5: von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments. J Am Med Dir Assoc. 2014 Dec;15(12):866-72. doi: 10.1016/j.jamda.2014.09.007. Epub 2014 Nov 20. PubMed PMID: 25455531.

6: von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):261-3. doi: 10.1007/s13539-014-0164-8. PubMed PMID: 25384990; PubMed Central PMCID: PMC4248411.

7: Salsman JM, Beaumont JL, Wortman K, Yan Y, Friend J, Cella D. Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia. Support Care Cancer. 2015 May;23(5):1355-64. doi: 10.1007/s00520-014-2484-9. Epub 2014 Oct 29. PubMed PMID: 25351456; PubMed Central PMCID: PMC4376952.

8: Pietra C, Takeda Y, Tazawa-Ogata N, Minami M, Yuanfeng X, Duus EM, Northrup R. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):329-37. doi: 10.1007/s13539-014-0159-5. Epub 2014 Sep 30. PubMed PMID: 25267366; PubMed Central PMCID: PMC4248409.

9: Ebner N, Steinbeck L, Doehner W, Anker SD, von Haehling S. Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies. J Cachexia Sarcopenia Muscle. 2014 Mar;5(1):27-34. doi: 10.1007/s13539-014-0136-z. Epub 2014 Mar 5. PubMed PMID: 24595460; PubMed Central PMCID: PMC3953317.

10: Currow DC, Abernethy AP. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Future Oncol. 2014 Apr;10(5):789-802. doi: 10.2217/fon.14.14. Epub 2014 Jan 28. PubMed PMID: 24472001.